FR06C0021I1 - - Google Patents

Info

Publication number
FR06C0021I1
FR06C0021I1 FR06C0021C FR06C0021I1 FR 06C0021 I1 FR06C0021 I1 FR 06C0021I1 FR 06C0021 C FR06C0021 C FR 06C0021C FR 06C0021 I1 FR06C0021 I1 FR 06C0021I1
Authority
FR
France
Prior art keywords
nucleic acid
vegf nucleic
acid ligand
immunogenic
molecular weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/739,109 external-priority patent/US5859228A/en
Priority claimed from US08/870,930 external-priority patent/US6168778B1/en
Priority claimed from US08/897,351 external-priority patent/US6051698A/en
Application filed filed Critical
Publication of FR06C0021I1 publication Critical patent/FR06C0021I1/fr
Application granted granted Critical
Publication of FR06C0021I2 publication Critical patent/FR06C0021I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR06C0021C 1996-10-25 2006-07-03 Complexes a base de ligands d'acide nucleique de facteur de croissance endothelial vasculaire Active FR06C0021I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/739,109 US5859228A (en) 1995-05-04 1996-10-25 Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US08/870,930 US6168778B1 (en) 1990-06-11 1997-06-06 Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US08/897,351 US6051698A (en) 1997-06-06 1997-07-21 Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
PCT/US1997/018944 WO1998018480A1 (en) 1996-10-25 1997-10-17 Vascular endothelial growth factor (vegf) nucleic acid ligand complexes

Publications (2)

Publication Number Publication Date
FR06C0021I1 true FR06C0021I1 (de) 2006-10-13
FR06C0021I2 FR06C0021I2 (fr) 2007-08-03

Family

ID=27419245

Family Applications (1)

Application Number Title Priority Date Filing Date
FR06C0021C Active FR06C0021I2 (fr) 1996-10-25 2006-07-03 Complexes a base de ligands d'acide nucleique de facteur de croissance endothelial vasculaire

Country Status (18)

Country Link
EP (2) EP1685842A3 (de)
JP (2) JP3626503B2 (de)
KR (1) KR100514929B1 (de)
AT (1) ATE318143T1 (de)
AU (1) AU733674B2 (de)
CA (1) CA2269072C (de)
DE (3) DE69735292T2 (de)
DK (1) DK0957929T3 (de)
ES (1) ES2259188T3 (de)
FR (1) FR06C0021I2 (de)
GE (1) GEP20094799B (de)
IL (2) IL129497A0 (de)
LU (1) LU91252I2 (de)
NL (1) NL300234I2 (de)
NZ (1) NZ334859A (de)
PT (1) PT957929E (de)
RU (1) RU2177950C2 (de)
WO (1) WO1998018480A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232071B1 (en) * 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US6346611B1 (en) 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
AU782620B2 (en) * 1991-06-10 2005-08-11 Gilead Sciences, Inc. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
US6762290B1 (en) * 1999-07-29 2004-07-13 Gilead Sciences, Inc. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
KR100758158B1 (ko) 1999-07-14 2007-09-12 알자 코포레이션 중성 지질중합체 및 그를 함유하는 리포솜 조성물
US7312325B2 (en) * 2000-09-26 2007-12-25 Duke University RNA aptamers and methods for identifying the same
EP1438321B1 (de) * 2001-10-26 2010-05-26 Noxxon Pharma AG Modifizierte l-nukleinsäure
GEP20063755B (en) * 2001-11-09 2006-02-27 Eyetech Pharmaceuticals Use of VEGF Inhibiting Agents for Treating Ocular Neovascular Diseases
US7767803B2 (en) 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
JP2005533862A (ja) 2002-07-25 2005-11-10 アーケミックス コーポレイション 調節されたアプタマー治療剤
US9303262B2 (en) 2002-09-17 2016-04-05 Archemix Llc Methods for identifying aptamer regulators
US10100316B2 (en) 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US8039443B2 (en) 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
CA2506748A1 (en) 2002-12-03 2004-06-17 Archemix Corporation Method for in vitro selection of 2'-substituted nucleic acids
FR2852606A1 (fr) * 2003-03-18 2004-09-24 Inst Nat Sante Rech Med Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
CA2523260A1 (en) 2003-04-21 2004-11-04 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
CL2004001996A1 (es) * 2003-08-08 2005-05-06 Eyetech Pharmaceuticals Inc Aptameros anti-vegf (factor de crecimiento endotelial vascular) con bloqueo nucleotidico 5'-5' o 3'-3' invertido, composicion que lo contiene, util para trastornos de neovascularizacion.
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
HUE050481T2 (hu) 2004-02-12 2020-12-28 Archemix Llc Aptamer terapeutikumok, amelyek használhatók komplementtel kapcsolatos rendellenességek kezelésében
US20050260153A1 (en) * 2004-04-13 2005-11-24 Pericles Calias Facilitation of iontophoresis using charged moieties
US7579450B2 (en) 2004-04-26 2009-08-25 Archemix Corp. Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
EP2436391A3 (de) 2004-11-02 2012-07-04 Archemix LLC Stabilisierte Aptamere für einen aus Plättchen gewonnenen Wachstumsfaktor und ihre Verwendung als Krebstherapiemittel
EP1907590B1 (de) 2005-06-30 2012-09-19 Archemix LLC T7 rna polymerase und verfahren zur herstellung von vollständig 2'-modifizierten nukleinsäuretranskripten
US8101385B2 (en) 2005-06-30 2012-01-24 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
EP1912676A2 (de) * 2005-07-28 2008-04-23 (Osi) Eyetech, Inc. Polymerkonjugat mit cyclitol-linker
JP2009504803A (ja) 2005-08-22 2009-02-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｔｌｒアゴニスト
KR100877824B1 (ko) 2005-11-11 2009-01-12 한국생명공학연구원 Ｅ2ｅｐｆ ｕｃｐ-ｖｈｌ 상호작용 및 그 용도
TW200804425A (en) * 2005-12-06 2008-01-16 Domantis Ltd Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor
AU2006325030B2 (en) * 2005-12-16 2012-07-26 Cellectis Cell penetrating peptide conjugates for delivering nucleic acids into cells
US20090175930A1 (en) * 2006-01-11 2009-07-09 Nobuhiro Yagi Composition Suppressing The Expression of Target Gene in Eyeball and Medicament For Treating of Disease in Eyeball
SI2596807T1 (sl) 2006-03-08 2016-03-31 Archemix Llc Komplement vezavni aptameri in sredstva proti C5, uporabni pri zdravljenju očesnih motenj
EA019151B1 (ru) 2007-02-07 2014-01-30 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния Конъюгаты синтетических агонистов tlr и их применение
US20110229498A1 (en) 2008-05-08 2011-09-22 The Johns Hopkins University Compositions and methods for modulating an immune response
EP2370581B1 (de) * 2008-12-04 2016-08-03 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem vaskulären endothelialen wachstumsfaktor (vegf) mittels hemmung des natürlichen antisense-transkripts gegen vegf
WO2010108108A2 (en) * 2009-03-20 2010-09-23 Egen, Inc. Polyamine derivatives
US20120295811A1 (en) 2009-11-23 2012-11-22 Jean-Jacques Toulme Aptamers directed against the matrix protein-1 of type a influenza viruses and uses thereof
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
CA2811601A1 (en) * 2010-09-24 2012-03-29 Mallinckrodt Llc Aptamer conjugates for targeting of therapeutic and/or diagnostic nanocarriers
US20150337308A1 (en) 2012-04-11 2015-11-26 Chu De Bordeaux Matrix metalloproteinase 9 (mmp-9) aptamer and uses thereof
CA2928520C (en) 2012-10-23 2023-03-14 Caris Life Sciences Switzerland Holdings, S.A.R.L. Aptamers and uses thereof
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
EP2935628B1 (de) 2012-12-19 2018-03-21 Caris Life Sciences Switzerland Holdings GmbH Zusammensetzungen und verfahren für aptamer-screening
KR101807590B1 (ko) 2013-03-22 2017-12-11 고쿠리츠다이가쿠호징 도쿄다이가쿠 Il-17에 대한 앱타머 및 그 사용
EP3019243A4 (de) 2013-07-12 2017-03-15 Ophthotech Corporation Verfahren zur behandlung oder prävention von augenerkrankungen
JP2016533752A (ja) 2013-08-28 2016-11-04 カリス ライフ サイエンシズ スウィッツァーランド ホー オリゴヌクレオチドプローブおよびその使用
JP7320919B2 (ja) 2014-12-11 2023-08-04 バイエル・ヘルスケア・エルエルシー 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療
US20180036409A1 (en) 2014-12-29 2018-02-08 Bonac Corporation Composition containing nucleic acid molecule stably
CA2979361A1 (en) 2015-03-09 2016-09-15 Caris Science, Inc. Method of preparing oligonucleotide libraries
EP3314027A4 (de) 2015-06-29 2019-07-03 Caris Science, Inc. Therapeutische oligonukleotide
CA2993652A1 (en) 2015-07-28 2017-02-02 Caris Science, Inc. Targeted oligonucleotides
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
CA3018066A1 (en) 2016-03-18 2017-09-21 Caris Science, Inc. Oligonucleotide probes and uses thereof
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
US11293017B2 (en) 2016-05-25 2022-04-05 Caris Science, Inc. Oligonucleotide probes and uses thereof
EP3332812A1 (de) 2016-12-07 2018-06-13 Rheinische Friedrich-Wilhelms-Universität Bonn Nukleinsäurebasierte anordnung und verwendung der anordnung in der krebstherapie
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
TW201906635A (zh) 2017-07-04 2019-02-16 日商第一三共股份有限公司 伴隨視細胞變性的視網膜變性的疾病用藥
WO2019210097A1 (en) * 2018-04-25 2019-10-31 Vitrisa Therapeutics, Inc. Aptamers with stability, potency or half-life for enhanced safety and efficacy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010448A2 (en) * 1989-03-07 1990-09-20 Genentech, Inc. Covalent conjugates of lipid and oligonucleotide
US5849479A (en) * 1990-06-11 1998-12-15 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US5811533A (en) * 1990-06-11 1998-09-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US5459015A (en) * 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US6168778B1 (en) * 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes

Also Published As

Publication number Publication date
CA2269072A1 (en) 1998-05-07
IL129497A0 (en) 2000-02-29
EP1685842A3 (de) 2006-11-29
DE69735292T2 (de) 2006-10-19
NL300234I2 (nl) 2006-10-02
JP4160038B2 (ja) 2008-10-01
WO1998018480A1 (en) 1998-05-07
LU91252I2 (fr) 2006-08-14
JP2005046160A (ja) 2005-02-24
DE122006000029I2 (de) 2007-11-08
JP3626503B2 (ja) 2005-03-09
AU4990497A (en) 1998-05-22
ATE318143T1 (de) 2006-03-15
NZ334859A (en) 2001-02-23
DK0957929T3 (da) 2006-07-03
IL129497A (en) 2009-06-15
RU2177950C2 (ru) 2002-01-10
DE122006000029I1 (de) 2006-10-19
GEP20094799B (en) 2009-10-26
KR100514929B1 (ko) 2005-09-15
DE69735292D1 (de) 2006-04-27
FR06C0021I2 (fr) 2007-08-03
EP0957929A1 (de) 1999-11-24
JP2001505191A (ja) 2001-04-17
ES2259188T3 (es) 2006-09-16
CA2269072C (en) 2006-02-14
NL300234I1 (nl) 2006-09-01
KR20000052697A (ko) 2000-08-25
AU733674B2 (en) 2001-05-24
EP1685842A2 (de) 2006-08-02
EP0957929A4 (de) 2003-06-25
EP0957929B1 (de) 2006-02-22
PT957929E (pt) 2006-06-30

Similar Documents

Publication Publication Date Title
FR06C0021I1 (de)
EP0824541A4 (de) Nukleinsäureligand-komplexe
IL134648A0 (en) Tie ligand homologues
ATE277058T1 (de) Polyazomacrocyclofluoromonoalkylphosphensäure, ihre komplexe zur verwendung als kontrastmittel
ZA986373B (en) Support bis(phosphorus) ligands.
WO1991001621A3 (en) Composites and methods for making same
EP0310361A3 (de) Aus drei Verzahnungen bestehendes Konjugat und Verfahren zu seiner Verwendung
DE69109131D1 (de) Verfahren zur herstellung von molekularsieben, einschliesslich zeolithen, mit metallchelat-komplexen.
IT1240104B (it) Trasmissione a pulegge, in particolare per autoveicoli.
ZA967618B (en) Peroxo-containing metal complexes having amine oxide, phosphine oxide, arsine oxide, pyridine N-oxide or pyridine ligants as epoxidation catalysts.
NO903521D0 (no) Aromautleveringssystem for tyggegummi.
ZA976421B (en) New bis-platinum complexes with polyamine ligands as antitumor agents.
ATE226211T1 (de) Antitumor-wirksame bis-platin komplexe mit polymethylen-derivaten als liganden
EP0676310A3 (de) Zigarettenanzünder, vorzugsweise für Kraftfahrzeuge.
IT1228713B (it) Equipaggiamento elettrico di trazione, in particolare per veicoli da trasporto pubblico.
EP0648217A4 (de) Saccharoseliganden, verfahren zu ihrer herstellung, davon abgeleitete platinkomplexe und verfahren zu ihrer verwendung.
DE68918620D1 (de) Magnetfluss-Betriebsverfahren für einen Induktionsmotor.
IT1237242B (it) Consolle per telefono, in particolare per autoveicoli.
NL189664C (nl) Vorkhefwagen voorzien van een weeginrichting, alsmede vork voor een dergelijke vorkhefwagen.
DE69003107D1 (de) Mit bor komplexierte organische phosphor-verbindungen.
IT9048012A0 (it) Cassettino porta-oggeti, in particolare per autoveicoli.
DE3870898D1 (de) 4-tert.-butyl-1,2-benzoldithiol, von ihm abgeleitete komplexverbindungen und verfahren zu ihrer herstellung.
DE58904373D1 (de) Wasserloesliche 2-naphthol-azoverbindungen, verfahren zu ihrer herstellung und ihre verwendung als farbstoffe.
IT8821824A0 (it) Posteggio di presentazione per autoveicoli, in particolare per automobili o autoveicoli per servizio promiscuo.
ES2018944A6 (es) Metodos de preparacion de tetraclorometalatos (ii) de 3-dialquil (aril) amino-5-fenil 1,2,4-ditiazolio.